BioLineRx Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q2 Results; BL-8040 Continues to be Main Driver
August 20, 2015 12:40 PM EDTRoth Capital affirms BioLineRx (NASDAQ: BLRX) with a Buy rating and $7 price target after BLRX reported quarterly results earlier Thursday.
BLRX posted Q2 EPS of ($0.12), which was $0.04 worse than the analyst estimate of ($0.08).
Analyst Joseph Pantginis offered the following commentary, We currently view BL-8040 as the main value driver for the company with multiple near-term milestones expected. The most significant... More
BioLineRx (BLRX) Misses Q2 EPS by 4c
August 20, 2015 7:05 AM EDTBioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08).
For earnings history and earnings-related data on BioLineRx (BLRX) click here.
... More